NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,…
Rethink Impact leads investment round as company targets expansion to 30+ states by end of 2026 WASHINGTON, DC / ACCESS…
Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for…
Strategic agreement leverages Garmin biometric data for digital health research OLATHE, Kan., Sept. 17, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) today…
Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase…
Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing…
Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing…
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation…
SJF Ventures invests in AI-powered digital maternal health platform driving better patient outcomes and addressing the maternal mortality crisis CUPERTINO,…
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate…